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Background: Pain upon the injection of propofol is a common adverse effect. This study was conducted to evaluate 
the analgesic effect of remifentanil and cold propofol during propofol injection for the induction of anesthesia and to 
determine if a combination of cold propofol and remifentanil produced additional analgesic efficacy. 
Methods: A total of 160 patients aged 20-65 years old were randomly allocated into one of four groups (n = 40, in 
each). Control and remifentanil group patients received 2 mg/kg propofol that had been stored at room temperature 
(20-23
oC), while the cold and combination group received cold (4
oC) propofol. The patients received remifentanil 0.5 
μg/kg IV in the remifentanil and combination groups or saline in the control and cold groups. Ninety seconds after 
administration the patients were administered propofol over a 30 second period. The pain intensity and incidence 
were then evaluated using a 4-point verbal rating scale. 
Results: The incidence of pain was significantly reduced in groups that received remifentanil in the cold and 
combination groups when compared with the control group (27.5%, 30%, and 2.5% vs. 70%, respectively). Moreover, 
the severity of pain was significantly lower in groups that received remifentanil in the cold and combination groups 
when compared with the control group. The incidence and severity of pain from the propofol injection in the 
combination group was significantly lower than that in the remifentanil and cold groups. 
Conclusions: The combination of cold propofol and pretreatment with remifentanil more effectively reduced the 
incidence of pain upon the injection of propofol than either treatment alone. (Korean J Anesthesiol 2010; 59: 305-309)
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Introduction
    Propofol (2,6-diisopropylphenol) is an intravenous hypnotic 
that has long been a popular choice for induction and 
maintenance of general anesthesia owing to its rapid onset and 
short duration. However, pain upon injection with propofol is 
a common problem that can be very distressing to the patient. 
The incidence of propofol injection pain has been reported to 
range from 80% to 90% when the veins on the dorsum of the 
hand are used for injection without treatment [1,2]. 
    Several investigators have studied pharmacological and 
nonpharmacological strategies for the prevention of pain upon 
propofol injection. Specifically, studies have been conducted to 
evaluate variations in the injection speed and carrier fluids [3], 
dilutions [4], and concomitant therapies using local anesthetics 
or opioids [5].  
    Pretreatment with remifentanil has been reported to reduce 
the incidence and severity of pain during propofol injection [6-9]. 
Iyilikci et al. [8] reported that remifentanil effectively prevented 
propofol injection pain, and that it should be administered at a 
dose of at least 0.02 mg for this purpose. Moreover, it has been 
reported that intravenous remifentanil 0.02 mg or remifentanil 
0.03 mg pretreatment effectively alleviates the pain associated 
with propofol injection [9]. However, the failure rate of this 
treatment was about 40% [8,9], and remifentanil did not 
completely control propofol-induced pain; thus, combination 
therapy has been suggested for the prevention of this pain [10]. 
Moreover, recent studies have revealed that a combination of 
two different analgesic modalities, opioids and lidocaine, can 
reduce the incidence and severity of propofol injection pain in 
adults when compared to administration alone [11,12]. Previous 
studies have suggested that chilling propofol leads to a decrease 
in the incidence of propofol injection [13,14]. However, there 
have been no reports of the use of combination cold propofol 
and pretreatment with remifentanil to reduce propofol injection 
pain. 
    This study was conducted to assess the effectiveness of cold 
propofol and pretreatment with remifentanil at minimizing the 
pain associated with the injection of propofol and to determine 
if a combination of cold propofol and remifentanil produced 
additional analgesic efficacy. 
Materials and Methods
    After obtaining approval from the Institutional Review 
Board and informed consent from the subjects, the study 
was conducted prospectively on 160 American Society of 
Anesthesiologists physical status I or II patients aged 20-65 
years who underwent general anesthesia for elective surgery. 
Patients who had known allergies to opioids or propfol; renal, 
hepatic, or cardiac problems; neurologic deficits or psychiatric 
disorders: or who had received analgesics or sedatives within the 
previous 24 hours were excluded. The patients were randomly 
assigned to one of four groups using an Excel (Microsoft 
Corp., Seoul, Korea) generated randomization table. The four 
groups were comparable with respect to patient characteristics 
(Table 1). No patients were excluded from the analysis due to 
complications; hence, the data for all 160 patients is presented. 
The induction dose of propofol (1% Anepol
Ⓡ, Hana Pharm. 
Co., Ltd., Hwasung, Korea) was 2 mg/kg. For the cold propofol, 
the propofol was drawn up in 20 ml syringes and maintained 
at a temperature of 4
oC in a refrigerator until ready for use. The 
control and remifentanil group patients received propofol 2 
mg/kg stored at room temperature (20-23
oC) and the cold and 
combination group received cold (4
oC) propofol. The patients 
received remifentanil 0.5 μg/kg IV in the remifentanil and 
combination groups, or saline in the control and cold groups 
over a 30 second period. Ninety seconds later, the patients 
were given propofol over a 30 second period. Blinding was 
maintained by the involvement of two practitioners (the drug 
manipulator and the anesthesia provider) at the induction of 
every patient. The drug manipulator prepared and injected the 
drugs, while the anesthesia provider assessed complications 
and pain and was blinded to the treatment group. 
    Premedication was not administered prior to the induction 
of anesthesia. Before arriving at the operating room, a 20 
gauge cannula was inserted in the left cephalic vein, and its 
position was confirmed by the free flow of Hartmann’s solution 
infused by gravity prior to the induction of anesthesia. Upon 
arrival at the operating room, all patients were evaluated 
based on electrocardiogram, pulse oximetry, non-invasive 
arterial pressure, and bispectral index score (BIS) monitoring. 
All patients were preoxygenated for five minutes prior to the 
induction of anesthesia. Following remifentanil or saline 
injection, propofol 2 mg/kg was administered through the 
rubber port connected to the intravenous cannula without the 
carrier fluid. The assessment of pain was made continuously 
from the start of the propofol injection to the point at which the 
patients lost consciousness. The severity of pain was assessed 
using a four-point scale. Pain manifested as a verbal response 
Table 1. Demographic Data
   Control
   (n = 40)
Remifentanil
(n = 40)
Cold
(n = 40)
Combination
(n = 40)
Sex (M/F)
Age (yr)
Weight (kg)
Height (cm)
  15/25  
49 ± 9.4
61.3 ± 10.3
162.5 ± 8.0
15/25
46 ± 12.0
60.6 ± 8.8
163.0 ± 6.9
14/26
48 ± 12.1
63.5 ± 11.2
163.6 ± 8.0
15/25
50 ± 11.0
59.9 ± 8.9
161.9 ± 6.6
The values shown are the means ± SD or the number of patients. 
There were no significant differences observed between groups.307 www.ekja.org
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accompanied by facial grimacing or withdrawal of the arm was 
scored as severe; grimacing or withdrawal not accompanied 
by a verbal response was scored as moderate pain. If severe or 
moderate pain was not observed, the patient was asked whether 
they had any discomfort in the arms. If they answered ‘yes’, this 
was scored as mild pain, if they answered ‘no’, this was scored 
as no pain [7].  
    Following the loss of an eyelash reflex, the patients were intu-
bated after administration of rocuronium 0.8 mg/kg. Anesthesia 
was then conducted at the anesthetist’s convenience. After 
remifentanil or saline injection, the BIS score was checked 
to subjectively assess the level of consciousness to ensure an 
adequate response to the pain questionnaires.
    The mean arterial pressure and heart rate were recorded prior 
to injection of the study drug (baseline), after the remifentanil 
injection, and before tracheal intubation. The chest wall rigidity, 
which was described as transient chest discomfort, was also 
recorded during remifentanil injection. Patients were monitored 
hourly for 24 hours post-surgery by a blinded investigator for 
adverse effects at the injection site (i.e., pain, edema, wheal, 
and flare response). 
    Based on previous studies [10], the incidence of injection pain 
in the cold or remifentanil group was expected to be ~40%. 
Therefore, 37 subjects per group would be needed to decrease 
this incidence to 5% (power 80% and a = 0.05). Additionally, 
we assumed a dropout rate of 10%; therefore, we increased the 
sample size to 40 patients per group.  
    Statistical analyses were conducted using SPSS (version 15.0, 
SPSS Inc., Chicago, IL, USA). Analyses of variance (ANOVA) was 
performed on the demographic data using the ANOVA test for 
continuous variables (i.e., age, height, and weight) and the chi-
square test for discrete variables (sex). The Fisher exact test was 
used to calculate between-group differences in the incidence 
of propofol-induced pain, and the Kruskal-Wallis rank test was 
used to assess differences in the mean pain-intensity scores. A P 
value < 0.05 was considered significant. All values are expressed 
as the mean (SD) or absolute value (%).
Results
    Both the incidence and severity of pain differed significantly 
among groups (P < 0.01). As shown in Table 2, the incidence 
and severity of pain was significantly reduced in the 
remifentanil, cold and combination groups when compared 
with the control group (P < 0.01).
    The incidence of pain from the propofol injection in the com-
bination group (2.5%) was significantly lower than that in the 
remifentanil and cold groups (27.5% and 30%, respectively, P < 
0.01, Table 2). In addition, the severity of pain was significantly 
lower in the combination group than the remifentanl and cold 
groups (P < 0.01). 
    Although the decrease in heart rate (HR) and mean arterial 
pressure (MAP) prior to intubation was statistically significant 
in all groups, the decrease in HR and MAP was not of clinical 
importance (Table 3). Additionally, none of the patients 
suffered from desaturation, apnea, or chest wall rigidity during 
the induction of anesthesia.
    For all subjects, the BIS score was above 90 prior to propofol 
injection, indicating adequate responses to questionnaires. 
There were no adverse effects at the injection site observed in 
any patients. 
Discussion 
    Our study demonstrated that combined treatment with 
remifentanil 0.5 μg/kg pretreatment and cold propofol 
significantly reduced the incidence and severity of propofol 
Table 2. Incidence and Severity of Pain upon Propofol Injection
Severity of pain
Control
(n = 40)
Remifentanil
(n = 40)
Cold
(n = 40)
Combination
(n = 40)
1 (no pain)
2 (mild pain)
3 (moderate pain)
4 (severe pain)
12 (30)
16 (40)
11 (27.5)
1 (2.5) 
29 (72.5)*
11 (27.5)*
0
0
28 (70)*
12 (30)*
0
0
39 (97.5)*,†
1 (2.5)*,†
0
0
The values shown are the number of patients (%). *P < 0.05 when 
compared to the control group, 
†P < 0.05 when compared to the 
remifentanil group and the cold group.
Table 3. Changes in the Mean Arterial Blood Pressure (MAP) and Heart Rate (HR)
MAP HR
Baseline After injection
Before
intubation
Baseline After injection
Before
intubation
Control
Cold
Remifentanil
Combination
98.7 ± 11.0
98.3 ± 11.9
99.3 ± 11.6
92.6 ± 13.3
92.2 ± 15.4
92.1 ± 15.6
94.3 ± 18.1
90.5 ± 13.4
79.4 ± 8.7*
82.8 ± 13.2*
77.5 ± 8.8*
72.1 ± 10.9*
78.2 ± 9.8
80.3 ± 16.9
75.2 ± 12.7
74.1 ± 10.4
80.2 ± 11.1
73.2 ± 12.1
73.1 ± 11.3
73.9 ± 10.1
68.4 ± 8.9*
76.7 ± 14.5*
63.5 ± 8.6*
62.3 ± 6.8*
Data shown are the means ± SD. Baseline: before administration of drugs, After injection: after remifentanil or saline injection. *P < 0.05 when 
compared to base line.308 www.ekja.org
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injection pain when compared with each treatment alone.
    To date, the mechanism by which propofol causes pain upon 
injection is not fully understood. 
    In studies examining strategies for the prevention of propofol-
induced pain [15], the activation of pain mediators such as the 
kinin cascade system has been suggested as a possible cause. 
    Many factors that influence pain during propofol injection 
have been identified, including temperature [13,14], the size of 
the vein and speed of injection [15], the site of the IV cannula 
[16], dilution [4] and sedative medication [17].  
    It has also been reported that the incidence and severity of 
pain during propofol injection were related to the formulation 
of propofol [18,19]. Larsen et al. [18] has reported that a new 
formulation of propofol (a 10% fat emulsion formulated with 
long- and medium-chain triglycerides) may be associated 
with less pain upon injection. Microemulsion of propofol 
produces more frequent and severe pain upon injection than 
lipid emulsion propofol, which may be attributable to higher 
concentrations of aqueous free propofol [19]. 
    Remifentanil is a synthetic and esterase-metabolized opioid 
with a rapid onset, an ultrashort duration of action, and a short 
context-sensitive half-time when compared with other opioids 
[20]. Several investigators have reported that remifentanil 
administered via bolus injection or continuous infusion 
effectively reduces propofol injection pain with varying results 
[6-9]. It has also been reported that intravenous remifentanil 
0.02 mg or remifentanil 0.03 mg pretreatment is effective at 
alleviating the pain associated with a propofol injection to 
40% and 30% of that reported without pretreatment [9]. In 
the present study, pretreatment with remifentanil 0.5 μg/kg 
significantly reduced the incidence of propofol injection pain 
from 70% to 27.5%, which is comparable with of the results 
observed in other studies [8,9]. 
    We assumed that the pain-reducing action of remifentanil was 
primarily central because a tourniquet technique was not used 
and adequate time was allowed for the onset of remifentanil 
(90 s). Moreover, it has been reported that intravenous opioids 
administered as Bier’s block prior to propofol injection failed to 
show analgesic efficacy [21,22]. 
    Changing the temperature of administered propofol has 
produced conflicting results in adults. Two studies demon-
strated reduced pain in response to treatment with cold propofol 
[13,14], and it has been suggested that this mechanism may 
occur due to the decreased speed of the kinin cascade and the 
stabilization of local pain mediators at lower temperatures [13]. 
Conversely, two studies have failed to demonstrate a reduction 
in pain using cold propofol [23,24]. However, we found that 
administration of propofol at 4
oC reduced the incidence of 
injection pain from 70% to 30%, which is comparable to the 
results obtained in response to pretreatment with remifentanil 
at 0.5 μg/kg. 
    In this study, the incidence of injection pain of propofol 
was reduced to 2.5% of patients in the combination group. 
Conversely, 27.5% of patients in the remifentanil group and 30% 
of patients in the cold group suffered from painful injection. The 
mechanism involved in this synergistic interaction has not been 
identified; therefore, further study to elucidate this mechanism 
is warranted. 
    Although the decrease in HR and MAP prior to intubation 
was statistically significant in all groups, the decrease of HR 
and MAP was not of clinical importance. None of the patients 
suffered from desaturation, apnea or chest wall rigidity 
during the induction of anesthesia. For all subjects, the BIS 
score was greater than 90, indicating adequate responses to 
questionnaires. No adverse effects at the injection site were 
observed in any patient. 
    It is important to consider the findings presented here within 
the context of the limitation of the study. Specifically, we did not 
use higher doses of remifentanil for our study. Higher doses of 
remifentanil may have produced further reductions in propofol 
injection pain, which would be of clinical benefit if it is not 
associated with an increase in the incidence of complications. 
Seconds, Hanci et al. [25] reported that the phases of the 
menstrual cycle may have a significant role on injection pain 
of propofol in women. However, the comparison for pain 
incidence and intensity with menstrual cycle was not evaluated. 
Further studies should consider these limitations. 
    In conclusion, the combination of cold propofol and pretreat-
ment with remifentanil more effectively reduced the incidence 
and severity of pain upon injection of propofol than either 
treatment alone.
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